Can I Take Resveratrol with AOD-9604? A Women's Health Guide

What Is AOD-9604 and Why Are Women Using It?

AOD-9604, also called HGH fragment 176-191, is a synthetic peptide derived from the C-terminal end of human growth hormone. It does not bind to growth hormone receptors the way full-length GH does. Instead, it appears to act on beta-3 adrenergic receptors in adipose tissue, stimulating fat breakdown (lipolysis) and inhibiting fat storage (lipogenesis) without the insulin-resistance effects associated with exogenous GH 1.

Women are increasingly requesting AOD-9604 through 503A compounding pharmacies for fat reduction, particularly for visceral and subcutaneous adipose tissue that becomes harder to shift after perimenopause. It is not FDA-approved for any indication, and its legal status sits in a gray zone: the FDA removed it from the bulk substances list under consideration for compounded use in 2023, making compounded AOD-9604 technically impermissible under federal guidelines at many compounding pharmacies, though enforcement remains inconsistent 2.

How Does AOD-9604 Work Differently in Women?

Sex-specific pharmacokinetic data for AOD-9604 in women is nearly nonexistent. The original Metabolic Pharmaceuticals trials in the early 2000s enrolled mixed-sex cohorts, and the published data was not stratified by sex 3. What we do know from growth hormone physiology generally is that women have higher GH pulse amplitude, faster GH clearance, and greater GH-to-IGF-1 sensitivity than men 4. Whether these differences translate to altered AOD-9604 kinetics or response is extrapolated, not directly studied. This is an evidence gap you deserve to know about.

Estrogen also up-regulates GH receptor expression in liver and adipose tissue 5. In perimenopause and post-menopause, falling estrogen may reduce the background adipose sensitivity that AOD-9604 relies on, though this is mechanistically inferred rather than confirmed in clinical trials.

Life Stage Considerations for AOD-9604 Use

Reproductive years (18-40): The peptide may theoretically interact with IGF-1 signaling involved in ovarian function. No safety data exists in women of reproductive age.

Perimenopause: Visceral fat accumulation accelerates in perimenopause as estrogen declines 6. This is the life stage where clinicians most frequently see AOD-9604 requests, but also where adding a phytoestrogen like resveratrol creates the most hormone-related complexity.

Post-menopause: Fat redistribution to the abdomen is well-documented. Any agent that modulates adipose tissue requires careful consideration alongside existing HRT, SSRIs, or other CYP-metabolized drugs.

What Is Resveratrol and Why Do Women Take It?

Resveratrol is a polyphenol found in grape skins, red wine, and certain berries. It activates the sirtuin-1 (SIRT1) pathway, has antioxidant properties, and has been investigated for effects on glucose metabolism, cardiovascular risk, and longevity signaling 7. Women take it for general "anti-aging" benefits, cardiovascular protection, metabolic support, and, increasingly, as a perceived complement to peptide-based weight protocols.

Resveratrol's Estrogenic Activity: What It Means for You

Resveratrol binds to both estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ), with a relative binding affinity roughly 7,000-fold lower than estradiol for ERα 8. At typical supplement doses (150-500 mg/day), circulating resveratrol concentrations are unlikely to produce strong estrogenic effects systemically, but tissue-specific estrogenic activity, especially in breast and uterine tissue, cannot be ruled out.

The clinical relevance of this depends heavily on your hormonal status:

• Reproductive years: Low concern if ovarian estrogen production is normal. Weak phytoestrogen effect is likely masked.
• Perimenopause and post-menopause: With endogenous estrogen low or absent, even weak estrogenic stimulation from resveratrol may have proportionally larger effects at tissue level.
• ER-positive breast cancer history or BRCA mutation: Resveratrol's estrogenic activity is a reason to avoid high-dose supplementation. Discuss with your oncologist.
• Women on tamoxifen: Resveratrol inhibits CYP2D6 at higher doses, potentially reducing tamoxifen's conversion to its active metabolite endoxifen 9.

PCOS and Resveratrol

Resveratrol has a specific body of evidence in PCOS. A 2016 randomized controlled trial published in Endocrinology found that 1,500 mg/day of resveratrol over three months significantly reduced total testosterone and DHEA-S levels in women with PCOS, and improved insulin sensitivity 10. This is one of the stronger sex-specific datasets for resveratrol. If you have PCOS and are considering AOD-9604 for metabolic fat reduction, the resveratrol-PCOS evidence is more solid than anything available for AOD-9604 alone in PCOS.

The AOD-9604 and Resveratrol Interaction: What the Evidence Actually Shows

There is no published pharmacokinetic or pharmacodynamic study directly examining AOD-9604 combined with resveratrol in humans or animals. Full stop. Any clinician or supplement company claiming a studied synergistic "longevity and fat loss stack" is extrapolating from unrelated mechanisms.

To evaluate this combination responsibly, we can apply a three-axis interaction framework specific to this pair:

Axis 1: Pharmacokinetic (PK) interaction Does resveratrol change how AOD-9604 is absorbed, distributed, metabolized, or cleared?

AOD-9604 is a peptide administered subcutaneously. Peptides are largely broken down by tissue peptidases and circulating proteases rather than by hepatic CYP enzymes. This means CYP3A4 inhibition from resveratrol is unlikely to meaningfully affect AOD-9604 plasma levels. The PK interaction risk for this specific pair is probably low.

Axis 2: Pharmacodynamic (PD) interaction Do the two compounds act on overlapping or opposing biological pathways in ways that matter clinically?

This is where the concern is more real. AOD-9604 is proposed to stimulate beta-3 adrenergic receptor activity in adipose tissue, promoting lipolysis. Resveratrol activates SIRT1, which intersects with AMPK signaling and lipid metabolism 11. In theory, both agents push in the direction of fat oxidation, creating a potential additive pharmacodynamic effect. Whether this additive lipolytic signal is beneficial or produces unintended metabolic consequences (hypoglycemia in women with low fasting glucose, for example) is unknown.

Axis 3: Hormonal environment interaction Does resveratrol's estrogenic activity alter the hormonal context in which AOD-9604 acts on adipose tissue?

Estrogen modulates adipose beta-adrenergic receptor density and sensitivity 12. Adding a weak estrogen-like compound (resveratrol) alongside a beta-3-adrenergic-acting peptide (AOD-9604) in a post-menopausal woman with low endogenous estrogen creates a hormonal-signaling environment that has not been characterized in any trial. Caution is warranted here, not alarm, but caution.

Does the Timing of Doses Matter?

For CYP3A4-mediated PK interactions, dose separation of two to four hours can reduce peak inhibition exposure for oral drugs. Since AOD-9604 bypasses hepatic first-pass metabolism as a subcutaneous peptide, dose separation is not necessary for PK reasons. There is no published evidence that timing resveratrol away from AOD-9604 injection changes outcomes for this combination. Take resveratrol at whatever time fits your existing routine.

Who Should Be More Careful About This Combination?

Not every woman faces the same level of concern. Here is how to think about your personal risk profile:

Higher caution recommended

• Women with ER-positive breast cancer history, BRCA1/BRCA2 mutations, or a first-degree relative with hormone-sensitive cancer. Resveratrol's estrogenic activity adds an unstudied variable.
• Women taking tamoxifen, aromatase inhibitors, or hormonal contraceptives metabolized via CYP3A4 or CYP2D6. Resveratrol at doses above 500 mg/day may affect these pathways 9.
• Women with fibroids or endometriosis. Estrogen-sensitive tissue may respond to even weak estrogenic inputs. The data is thin, but the biological plausibility is enough to flag.
• Women with very low fasting glucose or history of hypoglycemia. Both SIRT1 activation and beta-adrenergic stimulation can lower fasting glucose, and the combined effect is uncharacterized.
• Women on anticoagulants (warfarin, direct oral anticoagulants). Resveratrol inhibits platelet aggregation and may potentiate anticoagulant effects 13.

Lower concern (but still discuss with your prescriber)

• Generally healthy women in reproductive years with no hormone-sensitive conditions and no CYP-metabolized prescription drugs.
• Post-menopausal women not on HRT and not using any CYP3A4-cleared medications, who want to trial one compound at a time to assess individual response.

Pregnancy, Lactation, and Contraception

This section is required reading if you are pregnant, breastfeeding, or trying to conceive.

AOD-9604 in Pregnancy

AOD-9604 has no pregnancy safety data in humans. It is a synthetic peptide that modulates adipose and potentially IGF-1 signaling. Growth hormone axis peptides have not been established as safe in pregnancy. AOD-9604 should not be used during pregnancy. If you become pregnant while using it, stop immediately and contact your OB-GYN. There is no FDA pregnancy category assigned because the compound is not FDA-approved; the absence of a category does not mean safety.

Resveratrol in Pregnancy

Resveratrol is classified as likely unsafe in pregnancy at supplement doses according to the Natural Medicines Database. Animal studies show that resveratrol can cross the placenta and has been associated with altered fetal pancreatic development and cardiac conduction in rodent models at high doses 14. Human data is absent. ACOG does not endorse resveratrol supplementation in pregnancy. Do not take resveratrol supplements during pregnancy.

Breastfeeding

Resveratrol is lipophilic and is expected to transfer into breast milk, though quantitative human lactation data is not available. The Natural Medicines Database rates it as possibly unsafe during lactation. AOD-9604 transfer into breast milk is unknown. Given the absence of safety data for either compound, neither should be used while breastfeeding.

Contraception Requirement

Neither AOD-9604 nor resveratrol is a recognized teratogen requiring specific contraception under current guidelines, but given the complete absence of pregnancy safety data for AOD-9604 and the animal-data concerns for high-dose resveratrol, any woman of reproductive age using either compound should use reliable contraception.

Women using hormonal contraception metabolized via CYP3A4 (including many combined oral contraceptives and the etonogestrel implant) should know that resveratrol at doses above 500 mg/day may modestly reduce contraceptive drug exposure. The clinical significance of this is unknown, but it warrants a conversation with your prescriber about barrier backup 15.

Monitoring If You Are Already Taking Both

If you are already using AOD-9604 and resveratrol together, stopping abruptly is not necessary unless you have one of the higher-risk conditions listed above. Here is a practical monitoring approach:

Blood work to consider at baseline and every three months:

• Fasting glucose and fasting insulin (HOMA-IR)
• Estradiol, FSH, and LH if you are perimenopausal and tracking cycle changes
• CBC and coagulation panel if you are on anticoagulants
• LFTs (liver function tests), as both compounds have rare hepatotoxic signals at high doses 16

Symptom signals to report to your prescriber:

• New breast tenderness or nipple discharge
• Changes in menstrual pattern (lighter, heavier, or absent periods)
• Unexpected hypoglycemic symptoms: shakiness, sweating, confusion
• Easy bruising or prolonged bleeding

What the Evidence Gaps Mean for You: An Honest Assessment

Women have been systematically under-represented in peptide research. The original AOD-9604 trials from Metabolic Pharmaceuticals enrolled primarily obese men 3. Resveratrol trials are somewhat better for women, particularly in PCOS 10 and cardiovascular risk 7, but the combination of these two agents has never been studied in any sex.

Clinicians on the WomanRx editorial board reviewed this gap. As reviewer Maya Okafor, MD, summarizes: "My position on AOD-9604 plus resveratrol is that the pharmacokinetic risk is probably low because the peptide bypasses hepatic metabolism, but the pharmacodynamic and hormonal-environment questions are genuinely open. I would not recommend this combination to any patient with a hormone-sensitive diagnosis until we have better data, and I would caution any perimenopausal patient to sequence these agents rather than run them simultaneously so we can actually tell what is doing what."

This is the honest clinical position: not panic, not permission, but a call for individualized decision-making with a prescriber who knows your full picture.

Who This Combination Is Right For and Who Should Avoid It

May be appropriate (with close prescriber oversight)

• Post-menopausal women with no hormone-sensitive history, no CYP-cleared medications, normal fasting glucose, and no coagulopathy, who want to trial one agent at a time with baseline and follow-up labs.
• Women with PCOS who have strong evidence for resveratrol's insulin-sensitizing benefit and who want to add AOD-9604 for adipose reduction, provided their prescriber monitors androgens, glucose, and menstrual patterns.

Should avoid this combination

• Pregnant or breastfeeding women (absolute contraindication for both agents).
• Women with ER-positive breast cancer history or on tamoxifen.
• Women with endometriosis or large fibroids (resveratrol estrogenic activity is an unstudied risk).
• Women on anticoagulants without hematology oversight.
• Women trying to conceive, given the absence of reproductive safety data for AOD-9604.

Practical Dosing and Sequencing Guidance

Because no head-to-head trial exists, sequencing rather than simultaneous initiation is the most defensible clinical approach:

1. Start with the agent that has stronger evidence for your primary goal. For PCOS-related insulin resistance, resveratrol at 500-1,500 mg/day has RCT support. For adipose-specific fat reduction, AOD-9604 at 250-500 mcg/day subcutaneous has older, limited trial data.
2. Run a single agent for eight to twelve weeks with baseline labs before adding the second.
3. If you add both, keep resveratrol at or below 500 mg/day to minimize CYP enzyme effects.
4. Recheck fasting glucose, estradiol, and LFTs at the three-month mark.
5. Report any new breast symptoms, menstrual changes, or bruising immediately.

There is no validated dosing window where resveratrol must be timed away from your AOD-9604 injection for pharmacokinetic reasons. Taking resveratrol with food in the morning and injecting AOD-9604 in the evening is a reasonable practical approach that some prescribers use, though this schedule lacks direct evidence.